For the entire treatment period , a higher proportion of patients in the PC/gefitinib arm versus gefitinib experienced possibly drug-related grade 3-4 treatment-emergent adverse events ( 39 of 114 [ 34 % ] versus 19 of 118 [ 16 % ] ; p = 0.002 ) .